Akışa dön
78/100 Bullish 26.05.2026 · 15:39 Finrend AI ⏱ 1 dk 👁 21 TR

Eli Lilly to Acquire Three Vaccine Companies for Up to $3.8 Billion

US-based pharmaceutical giant Eli Lilly has signed agreements to acquire three biotechnology companies—Curevo, LimmaTech Biologics, and Vaccine Company—to strengthen its research in infectious diseases and vaccines. The total purchase price could reach up to $3.8 billion, contingent on the achievement of certain milestones. Under the deal, Eli Lilly aims to integrate the vaccine development portfolios and technologies of these companies. The acquisitions are part of the company's strategy to develop new treatments and prevention methods against infectious diseases. Curevo focuses on shingles vaccines, LimmaTech Biologics develops vaccines against antibiotic resistance, and Vaccine Company has a broad range of vaccine candidates. These acquisitions will significantly enhance Eli Lilly's presence in the vaccine market. Financial details indicate that while the upfront cash payment for the initial phase of the deal has not been disclosed, achieving the total value of $3.8 billion requires specific clinical and commercial successes. The acquisitions are expected to close in the first half of 2025. This is not investment advice.

📊 LLY — Piyasa Yorumu

▲ up · 65%

The news indicates that Eli Lilly has made a significant investment in the vaccine field, which could enhance the company's growth potential. Technical indicators point to a strong uptrend: although the RSI at 73 is approaching overbought territory, the MACD remains above the signal line and positive. The price is trading well above the 20- and 50-day moving averages and has gained over 5% in the last 24 hours. The upward momentum may continue in the short term, but there is a risk of some profit-taking due to overbought signals.

RSI 14
73.5
MACD
15.91
24h Δ
5.13%

📊 NVAX — Piyasa Yorumu

▲ up · 60%

The news involves a major acquisition in the vaccine sector, which could increase interest in vaccine companies such as NVAX. Technical indicators point to overbought territory (RSI 77.46), bringing a risk of a short-term correction. While the MACD and moving averages support an uptrend, overbought conditions and a high daily gain (+12.18%) warrant caution. A short-term upward move is likely, but confidence is moderate due to correction risk.

RSI 14
77.5
MACD
0.23
24h Δ
12.18%

📊 NVCR — Piyasa Yorumu

▲ up · 60%

Although the news headline is not directly related to NVCR, Eli Lilly's acquisition of vaccine companies could increase interest in the biotechnology sector. NVCR's technical indicators are sending positive signals in the short term: the RSI at 68 is not approaching overbought territory, the MACD is above the signal line, and the price is above both the 20-day and 50-day moving averages. The 5.97% rise in the last 24 hours also supports the momentum. However, since the direct impact of the news may be limited, the upside expectation is expressed with moderate confidence.

RSI 14
68.2
MACD
0.16
24h Δ
5.97%

📊 MRK — Piyasa Yorumu

■ neutral · 60%

MRK stock has risen 5.75% in the last 24 hours, with its RSI approaching overbought territory at 66. While the MACD shows a positive outlook above the signal line, the acquisition news regarding Eli Lilly may not directly impact MRK. A new catalyst is needed for the uptrend to continue in the short term, although current momentum could be sustained. Therefore, a neutral stance is recommended due to directional uncertainty.

RSI 14
66.0
MACD
2.07
24h Δ
5.75%
Canlı Grafikler

🔗 İlgili haberler

🧬 Buna benzer

AI tarafından yeniden derlenmiştir. Yatırım tavsiyesi değildir.